359
Participants
Start Date
November 29, 2023
Primary Completion Date
December 4, 2024
Study Completion Date
December 4, 2024
LB-102
LB-102 is a dopamine D2/3 and 5HT7 antagonist.
Richmond Behavioral Associates, Staten Island
CenExel CBH, Gaithersburg
CenExel iResearch, Decatur
CenExel ACMR, Atlanta
Segal Institute for Clinical Research, Miami Lakes
Behavioral Clinical Research, Inc., Hollywood
CenExel RCA, Hollywood
Neuro-Behavioral Clinical Research, North Canton
Midwest Clinical Research Center, Dayton
Uptown Research Institute, Chicago
Pillar Clinical Research, Chicago
Woodland Internation Research Group, Little Rock
Pillar Clinical Research, Bentonville
Woodland Research Northwest, Rogers
Pillar Clinical Research, Richardson
InSite Clinical Research, DeSoto
Community Clinical Research, Austin
ProScience Research Group, Culver City
Synexus, Cerritos
CelExel Clinical Innovations, Bellflower
Synergy Research, Lemon Grove
CenExel CIT Riverside, Riverside
NRC Research Institute, Santa Ana
CelExel CNS, Garden Grove
CenExel HRI, Berlin
Lead Sponsor
LB Pharmaceuticals Inc.
INDUSTRY